• Raised approximately A$200 million (NZ$217 million) through a fully underwritten placement
• Funds will provide balance sheet capacity for future growth opportunities
• Placement strongly supported by existing and new investors across New Zealand, Australia and offshore

EBOS Group Limited ('EBOS') is pleased to announce the successful completion of the fully underwritten placement ('Placement') of approximately 5.9 million new fully paid ordinary shares ('New Shares'), raising approximately A$200 million (NZ$217 million). The issue price of NZ$36.65 represented a 5.0% discount to the closing price on NZX of NZ$38.56 per share, as at 10 April 2025. The Placement was strongly supported by a broad range of existing and new investors across New Zealand, Australia and offshore. Eligible shareholders who bid for an amount less than or equal to their 'pro rata' share of New Shares under the Placement and Retail Offer have been allocated their full bid on a best endeavours basis. The funds raised in excess of the amounts paid for the acquisitions of SVS Veterinary Supplies ('SVS') and the remaining 10% stake in Transmedic will provide further balance sheet capacity to fund additional future growth opportunities. EBOS also intends to conduct a non-underwritten retail offer to eligible existing shareholders to raise up to A$50 million (NZ$54 million), with the ability to accept oversubscriptions at EBOS' discretion ('Retail Offer').